|
Match
|
Document |
Document Title |
|
|
7378387 |
Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes
A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of...
|
|
|
7371372 |
Compositions comprising IMPDH inhibitors and uses thereof for treating HCV infection
The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or pegylated alpha-interferon and an IMPDH inhibitor...
|
|
|
7365165 |
IL-1 antagonist formulations
Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the...
|
|
|
7344709 |
Treatment of hepatitis C in the Asian population with subcutaneous interferon-beta
The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race,...
|
|
|
7294332 |
Combination therapy (temozolomide and α-IFN) for advanced cancer
There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and alpha interferon are administered in combination in amounts sufficient to achieve a...
|
|
|
7235232 |
Interferon alpha hybrids
Hybrid human interferon-α polypeptides, and the corresponding nucleic acid molecules, are disclosed. Pharmaceutical compositions comprising these peptides, and the use of these polypeptides to...
|
|
|
7232562 |
E38N interferon gamma polypeptide variants
A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence...
|
|
|
7230081 |
Interferon gamma conjugates
A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence...
|
|
|
7217413 |
Use of novel agents inducing cell death in synergy with interferons
The invention concerns the use of novel agents including cell death, and in particular, an agent for overexpression of the PML protein on nuclear bodies, combined with interferons, to induce the...
|
|
|
7214367 |
Orally-administered interferon-tau compositions and methods
The present invention includes interferon-tau (IFNτ) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell...
|
|
|
7208167 |
Treatment of hepatitis C with thymosin and peptide combination therapy
A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with...
|
|
|
7208148 |
Chemically modified cytokines
The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a...
|
|
|
7182942 |
Vaccine immunotherapy for immune suppressed patients
A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide...
|
|
|
7160554 |
Enhanced circulation effector composition and method
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the...
|
|
|
7153499 |
Vaccine immunotherapy for immune suppressed patients
The present invention provides a formulation for inhibiting metastasis which includes 150–600 units of IL-2, a nonsteroidal anti-inflammatory drug (NSAID), and cyclophosphamide. The present...
|
|
|
7150882 |
Enhanced circulation effector composition and method
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the...
|
|
|
7144574 |
Interferon β variants and conjugates
The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid...
|
|
|
7138546 |
Compounds and compositions for delivering active agents
Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
|
7138379 |
Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
The present invention is directed towards a method of potentiating the anti-growth effects of type I interferon (IFN) on cells in a target cell population comprising increasing the number of...
|
|
|
7138376 |
Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4′-disubstituted...
|
|
|
7118742 |
Ligand for herpes simplex virus entry mediator and methods of use
A novel polypeptide ligand, p30, or LIGHT, for herpes virus entry mediator, HVEM, is provided. LIGHT is useful for modulating immune responses and in inhibiting infection and/or subsequent...
|
|
|
7118737 |
Polymer-modified synthetic proteins
The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological...
|
|
|
7115578 |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
Ribavirin derivatives represented by the formula V, pharmaceutical compositions containing them as well as the use of the ribavirin derivatives represented by the formula V for the preparation of a...
|
|
|
7115263 |
Compositions and methods for treating hyperimmune response in the eye
The present invention comprises and utilizes methods and compositions for treating hyperimmune reactions in the eye. Compositions comprising antibodies to gamma interferon alone and in combination...
|
|
|
7105154 |
Method of treatment using interferon-tau
A method for treating a condition responsive to interferon therapy in a human subject is described. The method includes orally administering interferon-tau to the intestinal tract in an amount...
|
|
|
7094397 |
Methods and reagents for the treatment of multiple sclerosis
The invention features methods and reagents for the diagnosis, monitoring, and treatment of multiple sclerosis. The invention is based in part on the discovery that Chlamydia is present in...
|
|
|
7083782 |
Method of treatment using interferon-tau
Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFNτ are described. More specifically, a method of up-regulating the IL-10...
|
|
|
7074403 |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
|
|
|
7067129 |
Receptor specific transepithelial transport in therapeutics
The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke...
|
|
|
7052687 |
Human recombinant beta-interferon with improved solubility
The invention relates to variants of recombinant human beta interferon and to a method for the production thereof, wherein at least one of the following amino acids Leu (5), Phe(8), Phe(15),...
|
|
|
7052685 |
Methods for treatment of cutaneous T-cell lymphoma
A method and composition for treatment of advanced cutaneous T cell lymphoma is provided which involves administration of recombinant interleukin-12.
|
|
|
7041302 |
Therapeutic modulation of the tumor inflammatory response
The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1...
|
|
|
7041301 |
Interferon immunotherapy
A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant...
|
|
|
7038015 |
Interferon gamma polypeptide variants
The present invention relates to novel interferon gamma polypeptide variants having interferon gamma (IFNG) activity, methods for their preparation, pharmaceutical compositions comprising the...
|
|
|
7030086 |
Stabilized liquid polypeptide-containing pharmaceutical compositions
Stabilized liquid polypeptide-containing pharmaceutical compositions are provided. The compositions comprise an amino acid base, which serves as the primary stabilizing agent of the polypeptide,...
|
|
|
6995133 |
Utilization of interferon alpha 5 in the treatment of viral hepatopathies
The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFNα5 in the livers of patients with hepatitis C in...
|
|
|
6991785 |
Method for administering a cytokine to the central nervous system and the lymphatic system
The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory...
|
|
|
6989364 |
Methods for treating cardiac hypertrophy by administering IFN-γ
The invention concerns the treatment of cardiac hypertrophy by interferon-gamma (IFN-γ). Cardiac hypertrophy may result from a variety of diverse pathologic conditions, including myocardial...
|
|
|
6982081 |
Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU
A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after...
|
|
|
6979674 |
Polyol/oil suspensions for the sustained release of proteins
The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent. The...
|
|
|
6964761 |
Method of treating idiopathic pulmonary fibrosis with aerosolized IFN-γ
A method of treating idiophathic pulmonary fibrosis (IPF), comprising administering aerosolized interferon-γ in a therapeutically effective amount to achieve improved or ameliorated symptoms of IPF.
|
|
|
6962695 |
Modification of interferon alpha production
A process for the production of α-interferon comprising the steps: i) inducing of human leukocytes by means of a virus; ii) treating the leukocytes with an enhancing agent selected from: a)...
|
|
|
6958388 |
Interferon gamma polypeptide variants
When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this...
|
|
|
6956027 |
N-terminally chemically modified protein compositions and methods
Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and...
|
|
|
6946125 |
Methods of treating West Nile virus infection
The present invention provides methods of preventing or treating West Nile virus as well as infections caused by other viruses of the Flaviviridae family in animals comprising administering to the...
|
|
|
6943148 |
Methods for delivering therapeutics across blood-barrier and for altering receptor binding affinity
The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic...
|
|
|
6924270 |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
Ribavirin derivatives represented by the formula II, pharmaceutical compositions containing them as well as methods of using the ribavirin derivatives represented by the formula II for the...
|
|
|
6908611 |
Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
Pharmaceutical compositions for treating viral, proliferative and inflammatory diseases are disclosed comprising an amount of pharmaceutically acceptable vitamin B12 compound in combination with an...
|
|
|
6902729 |
Murine interferon-α
Interferons represent an important class of biopharmaceutical products, which have a proven track record in the treatment of a variety of medical conditions, including the treatment of certain...
|
|
|
6896879 |
Method of pre-sensitizing cancer prior to treatment with radiation and/or chemotherapy and a novel cytokine mixture
This invention relates to a breakthrough method for pre-sensitizing cancer prior to a therapeutic treatment such as chemotherapy, radiation therapy or immuno-therapy and a novel cytokine mixture...
|